Omic approaches to quality biomarkers for stored platelets: are we there yet?

Transfusion Medicine Reviews
Sandhya KulkarniChintamani D Atreya

Abstract

At present, there is no single biomarker that serves as the "gold standard" predictive of the quality of stored platelets used for transfusion. Some of the measurable features of platelets such as morphology, biochemical status, physiologic response to osmotic stress and agonist-induced changes, and measurement of process-associated activation indicators of platelets are considered useful in assessing the in vitro quality of stored platelets. Such in vitro measurements combined with in vivo survival estimations using radiolabeled platelets in healthy volunteers provide reasonable estimates of in vivo platelet function after transfusion. Thus, the current practice of estimating the quality and functional aspects of ex vivo stored platelets involves utilization of a battery of tests that dates back to pre-omic era. On the other hand, during the last decade, seminal discoveries have been made in platelet molecular and cell biology by using "omic"-based approaches such as proteomics, genomics, and transcriptomics. Can we mobilize some of these discoveries toward developing reliable quality biomarkers for stored platelets? To address this topic, we briefly review current practices and provide insights into some of the omic approache...Continue Reading

References

Apr 1, 1987·European Journal of Biochemistry·N KiefferJ Breton-Gorius
Feb 1, 1994·European Journal of Clinical Investigation·H Holmsen
Jan 1, 1996·Seminars in Thrombosis and Hemostasis·J Dachary-PrigentJ M Freyssinet
May 20, 1998·Proceedings of the National Academy of Sciences of the United States of America·A S WeyrichG A Zimmerman
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Jun 26, 2003·Transfusion·A M BertinoD J Kuter
Apr 8, 2006·Thrombosis and Haemostasis·Marcus DittrichThomas Dandekar
Jun 8, 2006·Vox Sanguinis·V S HornseyC V Prowse
Jun 22, 2007·Transfusion·Thomas ThieleAndreas Greinacher
Feb 28, 2008·Transfusion·Junichi HirayamaHisami Ikeda
Jul 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Patrick S MitchellMuneesh Tewari
Aug 5, 2008·Cancer Research·Troels SchepelerClaus L Andersen
Aug 21, 2008·Clinical Genetics·A E Erson, E M Petty
Aug 23, 2008·Cell Cycle·Pedro P Medina, Frank J Slack
Aug 30, 2008·The FEBS Journal·Sunit K SinghUtpal Bhadra
Aug 12, 2009·Nature Structural & Molecular Biology·Patricia LandryPatrick Provost

❮ Previous
Next ❯

Citations

Mar 23, 2011·Transfusion Medicine Reviews·Patricia Ryan, Chintamani Atreya
Apr 8, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·N LionJ-D Tissot
Dec 24, 2010·Vox Sanguinis·D V Devine, P Schubert
Jul 16, 2010·Expert Review of Molecular Diagnostics·Clark D Jeffries
Nov 18, 2011·Expert Review of Proteomics·Michel PrudentNiels Lion

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Current Opinion in Hematology
Lisa SenzelWadie F Bahou
Journal of Proteome Research
René P ZahediAlbert Sickmann
© 2021 Meta ULC. All rights reserved